Agresta F, Michelet I, Boni V, Tonietto G
Department of Surgery, Ospedale Civile, Vittorio Veneto, Treviso, Italy.
J Cardiovasc Surg (Torino). 1998 Oct;39(5):551-5.
The authors report their experience with thrombolytic therapy in seven cases of graft thrombosis managed successfully with low-dose i.v. rt-TPA. In six patients the cause was an anatomical one and so, after the successful lysis, there was enough time to confirm a correct diagnosis and plan the "right" and "less extensive" surgical procedure, obviating it in one case with a "functional" cause of thrombosis.
No complication directly attributable to rt-TPA infusion occurred, and no systemic fibrinogenolysis was registered in any cases. Judging from this experience, i.v. rt-TPA appears safe and effective in patients with graft thrombosis, proving to be a good adjunctive therapeutic mode.
Further studies are needed do delineate more clearly safe indication and the validity of this method.
作者报告了他们使用低剂量静脉注射重组组织型纤溶酶原激活剂（rt-TPA）成功治疗7例移植血管血栓形成的经验。6例患者的病因是解剖学原因，因此，在成功溶栓后，有足够时间确诊并规划“正确”且“范围较小”的手术，其中1例因血栓形成的“功能性”原因而避免了手术。
未发生直接归因于rt-TPA输注的并发症，所有病例均未出现全身性纤维蛋白溶解。根据这一经验，静脉注射rt-TPA在移植血管血栓形成患者中似乎是安全有效的，证明是一种良好的辅助治疗方式。
需要进一步研究以更明确地界定该方法的安全适应证和有效性。
